Interferon beta induction/interferon alpha therapy in patients with interferon-resistant chronic hepatitis C

Hepatology Research

Volumn 24, Issue 4, 2002, Pages 355-360

  Watanabe, Hiroshi ^a   Iwata, Kaoru ^a   Sohda, Tetsuro ^a   Sakisaka, Shotaro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; High levels of HCV RNA; IFN beta induction interferon alpha therapy; Interferon; Sustained response

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ANOREXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; HEPATITIS C; HUMAN; INTERFERON INDUCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036902011     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00146-8     Document Type: Article

References (21)

1. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
2. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, et al. Persistant hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 1996;124:1058-60.
3. Fukuma T, Enomoto N, Marumo F, Sato C. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Hepatology 1998;28:1147-53.
4. Nishiguchi S, Ueda T, Itoh T, Enomoto M, Tanaka M, Tatsumi M, et al. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy. Hepatology 2001;33:241-7.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
6. McHutchison JD, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustigi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
7. Knodell RG, Ishak KG, Black WG, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;5:431-5.
8. Desmet VJ, Gerber M, Hoofnagle JH, Manus M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
9. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon α-2b patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
10. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon α therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
11. Paayan JL, Izopet J, Garindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, et al. Better efficacy of a 12 months interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after 6 month treatment: multicenter, controlled, randomized trial. Hepatology 1998;28:1680-6.
12. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatits C viral dynamics in vivo and the antiviral efficacy of interferon-alfa therapy. Science 1998;282:103-7.
13. Ampurdanes S, Olmedo E, Maluenda MD, Forms X, Lopez-Labrador FX, Costa J, et al. Persistant response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 1996;25:827-32.
14. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, et al. Loss of serum HCV-RNA at week 4 of interferon-alfa therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-15.
15. Lee WM, Reddy R, Tong MJ, Black M, van Leeuwen DJ, Hollinger FB, et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998;28:1411-5.
16. Furusho N, Hayashi J, Ohmiya M, Sawayama Y, Akiyama I, Kinukawa N, et al. Differences between interferon-alfa and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 1999;44:608-17.
17. Domanski P, Nadeau OW, Platanias LC, Fish E, Kellum M, Pitha P, et al. Differential use of the βL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFN α 2 and IFN β. J Biol Chem 1998;273:3144-7.
18. Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, et al. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000;33:313-55.
19. Zeuzem S, Feinman V, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
20. Zeuzem S, Feinman V, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
21. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Safli M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The hepatitis C Intervention Therapy Group. Hepatology 2000;32:647-53.